Copyright
©The Author(s) 2022.
World J Gastroenterol. Aug 14, 2022; 28(30): 4182-4200
Published online Aug 14, 2022. doi: 10.3748/wjg.v28.i30.4182
Published online Aug 14, 2022. doi: 10.3748/wjg.v28.i30.4182
Figure 2 Cumulative incidences of hepatocellular carcinoma, decompensation, and death/transplantation in entire cohort.
A: Cumulative incidence of hepatocellular carcinoma in the untreated, interferon-based treatment (IBT), and direct-acting antivirals (DAA) groups; B: Cumulative incidence of decompensation in the untreated, IBT, and DAA groups; C: Cumulative incidence of death/transplantation in the untreated, IBT, and DAA groups. DAA: Direct-acting antivirals; HCC: Hepatocellular carcinoma; IBT: Interferon-based treatment.
- Citation: Choi GH, Jang ES, Kim YS, Lee YJ, Kim IH, Cho SB, Lee HC, Jang JW, Ki M, Choi HY, Baik D, Jeong SH. Hepatocellular carcinoma, decompensation, and mortality based on hepatitis C treatment: A prospective cohort study. World J Gastroenterol 2022; 28(30): 4182-4200
- URL: https://www.wjgnet.com/1007-9327/full/v28/i30/4182.htm
- DOI: https://dx.doi.org/10.3748/wjg.v28.i30.4182